Hydrogen fuel technology companies are reviewed. Biogen stock looks vulnerable as FDA approval of its new Alzheimer drug attracts criticism. Stocks hit highs, but not very convincingly.
For many years now, the famous BRICs have been touted as THE place to put your money for the best chance for long term capital growth.
However, the returns of many of the indices and managed funds in Emerging Markets have not reflected the growth nor the opportunity that we see in those markets.
We found the best Emerging Markets ETF to invest in!
With this stock out of favor yet showing some stable base building, investors are ignoring major catalyst occurring before month end.
Biogen’s new Alzheimer’s, drug approval has investors pondering whether this is enough of a change in mindset to reshape opinions about gene editing companies. Bets are being placed in the options market.
CBR blacklists Interactive Brokers and Exante and 1800+ other companies. Emerging Markets perform well. Our stock picks and Investment Strategies show strength. New trade ideas are presented also.
Waiting for the Seasonal sell signal in the NASDAQ, other sector trades come to and end in June. Gearing up for a sideways market is the plan now, until the strong months again come later this year.
MercadoLibre and PagSeguro are growing their fintech efforts.
AT&T cuts its dividend. Semiconductors remain newsworthy.
We see option activity picking up in our favorite Latin American payment service company. Morgan Stanley analysts expect stronger than expected growth. The chart looks interesting for the stock to run again.
Valuations are compelling in Emerging Markets, but momentum is weak. Seasonally, June is weak. Gold and silver show strength against dollar weakness.
Tesla, the best innovator with first mover advantage in EV space, gets all the attention. It has a lofty multiple while other auto makers were shunned. Recently, new products signal a change.
